INCIDENCE OF JAK2V617F MUTATION IN IRAQI PATIENTS WITH PHILADELPHIA POSITIVE CML

Marwah Hasan Abd Ali AL-Kaabi1; Yusra Ghiath Yaseen Al-Obaidy1; Shahla ́a Fadhil Sabir1; Israa Mohamed Safi AL-Kadmy

Abstract

INCIDENCE OF JAK2V617F MUTATION IN IRAQI PATIENTS WITH PHILADELPHIA POSITIVE CML

Author(s): Marwah Hasan Abd Ali AL-Kaabi1, Yusra Ghiath Yaseen Al-Obaidy1, Shahla Ìa Fadhil Sabir1and Israa Mohamed Safi AL-Kadmy

Objective:The aim of this study was to detect the occurrence of JAK2 V617F mutationin CML Iraqi patients. Methods: In this study 89 blood samples were collected from Iraqi CML patients who receiving imatinib mesylate or nilotinib as a treatment at National Center of Hematology during the period January 2013-June 2013, then DNA were extracted and ARMS-PCR technique was performed to detect the JAK2V617f mutation. Results:Out of 89 patients, JAK2V617F mutation was detected in only one patient (1.1%), a 52 year-old woman who was on Imatinib mesylate therapy for five years. Conclusion: Such rare patients with co-existingBCR-ABL translocation and JAK2V617F mutation must be identified in view of the possibility of targeted therapies

PDF